James Ackermann

James Ackermann

Auto-generated profile, based on publicly available information

James Ackermann

Department of Clinical Chemistry , Inselspital—University Hospital Bern , Bern , Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2023 in Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
HWHarald Witte
Harald Witte
TBTobias Ueli Blatter
Tobias Ueli Blatter
PNPriyanka Nagabhushana
Priyanka Nagabhushana
DSDavid Schär
David Schär
JAJames Ackermann
James Ackermann
ALAlexander Benedikt Leichtle
Alexander Benedikt Leichtle
The amount of data generated in the field of laboratory medicine has grown to an extent that conventional laboratory information systems (LISs) are struggling to manage and analyze this complex, entangled information (“Big Data”). Statistical learning, a generalized framework from machine learning (ML) and artificial intelligence (AI) is predestined for processing “Big Data” and holds the potential to revolutionize the field of laboratory medicine. Personalized medicine may in particular benefit from AI-based systems, especially when coupled with readily available wearables and smartphones which can collect health data from individual patients and offer new, cost-effective access routes to healthcare for patients worldwide. The amount of personal data collected, however, also raises concerns about patient-privacy and calls for clear ethical guidelines for “Big Data” research, including rigorous quality checks of data and algorithms to eliminate underlying bias and enable transparency. Likewise, novel federated privacy-preserving data processing approaches may reduce the need for centralized data storage. Generative AI-systems including large language models such as ChatGPT currently enter the stage to reshape clinical research, clinical decision-support systems, and healthcare delivery. In our opinion, AI-based systems have a tremendous potential to transform laboratory medicine, however, their opportunities should be weighed against the risks carefully. Despite all enthusiasm, we advocate for stringent added-value assessments, just as for any new drug or treatment. Human experts should carefully validate AI-based systems, including patient-privacy protection, to ensure quality, transparency, and public acceptance. In this opinion paper, data prerequisites, recent developments, chances, and limitations of statistical learning approaches are highlighted.